Drug intelligence / Profile preview

cyclophosphamide + vindelsine + cytarabine + doxorubicin + prednisone

Development stage: Unknown
Lead developer: Chinese Children's Cancer Group
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This multi-agent chemotherapy combination regimen, often referred to as 'Course A' within the Chinese Children's Cancer Group (CCCG) protocols, is used for the treatment of pediatric mature B-cell non-Hodgkin lymphoma (B-NHL). The regimen is an intensive, LMB-based (Lymphomes Malins B) chemotherapy block consisting of cyclophosphamide, vindelsine, cytarabine, doxorubicin, and prednisone. It is typically evaluated in Phase 3 clinical trials in China, often in conjunction with rituximab, to treat aggressive B-cell lymphomas such as Burkitt lymphoma and large B-cell lymphoma in children and adolescents. Each component targets different stages of the cell cycle or cellular processes: cyclophosphamide acts as an alkylating agent, vindelsine (a variant of vindesine) disrupts microtubule assembly, cytarabine inhibits DNA synthesis, doxorubicin inhibits topoisomerase II, and prednisone provides lympholytic effects through glucocorticoid receptor activation.

Other names: cyclophosphamide + vindesine + cytarabine + doxorubicin + prednisoneCourse A-type chemotherapy

Targets

DNA polymerase familyTOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on cyclophosphamide + vindelsine + cytarabine + doxorubicin + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + vindelsine + cytarabine + doxorubicin + prednisone.

Explore the full profile